Arax Advisory Partners’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
GCL
HI
Arax Advisory Partners's CPRX Position: Q2 2026 in Review
Arax Advisory Partners increased its Catalyst Pharmaceutical (CPRX) stake by 1,106% in Q2 2026, buying an estimated $45.7K and bringing the position to 1,688 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3216.
Arax Advisory Partners first reported a position in CPRX in Q2 2024 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- Arax Advisory Partners held 1,688 shares of Catalyst Pharmaceutical worth $53.1K as of Q2 2026.
- Arax Advisory Partners bought 1,548 Catalyst Pharmaceutical shares in Q2 2026, an estimated $45.7K.
- Catalyst Pharmaceutical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3216 holding.
- Arax Advisory Partners first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 6 quarters since.
- 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.